OKYO Pharma Limited
OKYO
$-0.03
Change (1 day)
$2.12
Year High
$0.81
Year Low
Categories
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Earnings for OKYO Pharma Limited (OKYO)
Earnings in 2024 (TTM): $-16,803
According to OKYO Pharma Limited's latest financial reports the company's current earnings (TTM) are $-16,803. The earnings displayed on this page is the company's Pretax Income.
Earnings history of OKYO Pharma Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-16,803 | $-16,825 |
| 2023 | $-13,283,887 | $-13,271,685 |
| 2022 | $-6,217,566 | $-5,431,045 |
| 2021 | $-3,378,501 | $-3,353,507 |
| 2020 | $-1,618,344 | $-1,542,149 |
| 2019 | $-4,902,470 | $-4,902,470 |
| 2018 | $-28,266,933 | $-28,266,933 |
| 2017 | $-241,927 | $-241,927 |
| 2016 | $-1,010,159 | $-820,171 |
| 2015 | $-1,494,369 | $-8,255,049 |
| 2014 | $-13,926,625 | $-13,926,625 |
| 2013 | $-4,655,698 | $-4,655,698 |
| 2012 | $-5,699,523 | $-4,804,369 |
| 2011 | $-1,616,636 | $-1,616,636 |
| 2010 | $12.67 M | $12.67 M |
| 2009 | $14.33 M | $14.33 M |
| 2008 | $-2,974,560 | $-2,974,560 |